BioSpace News Archive

- Objectives of KIDCARES10 Study (KIg10 in peDiatric subjects: effiCacy, sAfety and phaRmacokinEticS of a 10% IG) a phase III, open-label, prospective, multi-center study are to assess the efficacy, safety, and pharmacokinetics of a 10 percent intravenous immunoglobulin (IVIG) in pediatric patients aged 2 to 17 years and affected by primary immunodeficiency disease (PI)

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced the sale of its minority share in Q 2 Solutions to IQVIA (NYSE: IQV)

Athersys, Inc. (NASDAQ: ATHX) announced today that Mr. Ivor Macleod, Chief Financial Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Wednesday, April 14, 2021 at 1:30 pm EDT.

New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension – Results show patients treated with sotatercept experienced improvements in hemodynamic and functional endpoints compared with placebo –

Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021

Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks

Fact.MR, Rockville MD: The glaucoma diagnostics market is anticipated to post substantial gains through 2021 and beyond, as ophthalmic clinics resume elective surgeries in the post-pandemic scenario.

Constant improvement in surgical treatment and heavy investment in R&D will stimulate the sales of iridocorneal endothelial syndrome

Fact.MR, Rockville MD: Fact.MR’s ongoing nicotine testing market study projects a positive growth trajectory through 2021, with an increasing number of tobacco consumers seeking rehabilitation and cessation approaches.

The global audiological devices market was valued at US$ 8.7 Bn in 2017. It is projected to expand at a compound annual growth rate of 5.0% from 2018 to 2026, according to a new report published by Transparency Market Research titled “Audiological Devices Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.